1: Warner FJ, Miller RC, Burcher E. Structure-activity relationship of neurokinin A(4-10) at the human tachykinin NK(2) receptor: the effect of amino acid substitutions on receptor affinity and function. Biochem Pharmacol. 2002 Jun 15;63(12):2181-6. PubMed PMID: 12110377.
2: Patak EN, Ziccone S, Story ME, Fleming AJ, Lilley A, Pennefather JN. Activation of neurokinin NK(2) receptors by tachykinin peptides causes contraction of uterus in pregnant women near term. Mol Hum Reprod. 2000 Jun;6(6):549-54. PubMed PMID: 10825373.
3: Dougherty PM, Palecek J, Palecková V, Willis WD. Neurokinin 1 and 2 antagonists attenuate the responses and NK1 antagonists prevent the sensitization of primate spinothalamic tract neurons after intradermal capsaicin. J Neurophysiol. 1994 Oct;72(4):1464-75. PubMed PMID: 7823080.
4: Naline E, Devillier P, Drapeau G, Toty L, Bakdach H, Regoli D, Advenier C. Characterization of neurokinin effects and receptor selectivity in human isolated bronchi. Am Rev Respir Dis. 1989 Sep;140(3):679-86. PubMed PMID: 2476956.
5: Mazzone SB, Geraghty DP. Respiratory actions of tachykinins in the nucleus of the solitary tract: characterization of receptors using selective agonists and antagonists. Br J Pharmacol. 2000 Mar;129(6):1121-31. PubMed PMID: 10725260; PubMed Central PMCID: PMC1571949.
6: Liu L, Shang F, Markus I, Burcher E. Roles of substance P receptors in human colon circular muscle: alterations in diverticular disease. J Pharmacol Exp Ther. 2002 Aug;302(2):627-35. PubMed PMID: 12130725.
7: Burcher E, Shang F, Warner FJ, Du Q, Lubowski DZ, King DW, Liu L. Tachykinin NK2 receptor and functional mechanisms in human colon: changes with indomethacin and in diverticular disease and ulcerative colitis. J Pharmacol Exp Ther. 2008 Jan;324(1):170-8. Epub 2007 Oct 24. PubMed PMID: 17959748.
8: Liu L, Shang F, Morgan MJ, King DW, Lubowski DZ, Burcher E. Cyclooxygenase-dependent alterations in substance P-mediated contractility and tachykinin NK1 receptor expression in the colonic circular muscle of patients with slow transit constipation. J Pharmacol Exp Ther. 2009 Apr;329(1):282-9. doi: 10.1124/jpet.108.148148. Epub 2009 Jan 22. PubMed PMID: 19164461.
9: Rovero P, Pestellini V, Patacchini R, Giuliani S, Maggi CA, Meli A, Giachetti A. Synthesis and biological activity of NK-2 selective tachykinin antagonists containing D-tryptophan. Peptides. 1990 May-Jun;11(3):619-20. PubMed PMID: 2166282.
10: Turcatti G, Vogel H, Chollet A. Probing the binding domain of the NK2 receptor with fluorescent ligands: evidence that heptapeptide agonists and antagonists bind differently. Biochemistry. 1995 Mar 28;34(12):3972-80. PubMed PMID: 7696262.
11: Kullmann FA, Katofiasc M, Thor KB, Marson L. Pharmacodynamic evaluation of Lys(5), MeLeu(9), Nle(10)-NKA((4-10)) prokinetic effects on bladder and colon activity in acute spinal cord transected and spinally intact rats. Naunyn Schmiedebergs Arch Pharmacol. 2017 Feb;390(2):163-173. doi: 10.1007/s00210-016-1317-4. Epub 2016 Nov 26. PubMed PMID: 27889808; PubMed Central PMCID: PMC5512890.
12: Mazzone SB, Geraghty DP. Respiratory actions of tachykinins in the nucleus of the solitary tract: effect of neonatal capsaicin pretreatment. Br J Pharmacol. 2000 Mar;129(6):1132-9. PubMed PMID: 10725261; PubMed Central PMCID: PMC1571950.
13: Gembitsky DS, Murnin M, Otvös FL, Allen J, Murphy RF, Lovas S. Importance of the aromatic residue at position 6 of [Nle(10)]neurokinin A(4-10) for binding to the NK-2 receptor and receptor activation. J Med Chem. 1999 Jul 29;42(15):3004-7. PubMed PMID: 10425111.